Investing in Global Blood Therapeutics, Inc. (GBT)  ➔  Intrinsic value

Prev. close$28.03 
ModelValueUpside
Chepakovich$0.53-98%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$28.03  
Valuation MethodValuePotential 
Chepakovich Model$0.53-98%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.